What is the role of a PET scan in the workup of cerebral amyloid angiopathy (CAA)?

Updated: Dec 19, 2018
  • Author: Ravi S Menon, MD; Chief Editor: Helmi L Lutsep, MD  more...
  • Print


Florbetapir F18 (AMYViD) was approved by the FDA in April 2012 as a diagnostic imaging agent. It is indicated for PET brain imaging of beta-amyloid neuritic plagues in adults being evaluated for Alzheimer disease or other cognitive decline. A second 18F-labeled Pittsburgh compound B (PIB) derivative, flutemetamol F18 (Vizamyl), was also approved in October 2013.

A third agent, florbetaben F 18 (Neuraceq), was approved by the FDA in March 2014. Images may be obtained between 45-130 minutes following the injected dose. FDA approval was based on safety data from 872 patients who participated in global clinical trials as well as 3 studies that examined images from adults with a range of cognitive function, including 205 end-of-life patients who had agreed to participate in a post-mortem brain donation program. Images were analyzed from 82 subjects with post-mortem confirmation of the presence or absence of beta-amyloid neuritic plaques. [10]

In PET scanning, cortical retention of Pittsburgh Compound B (binds beta-amyloid) may serve as an in vivo marker of CAA in humans. [11]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!